



April 1, 2022

## Interview With Bart De Wever, Bonyf Scientific Director

### **Boursier.com: Bonyf discreetly listed on the Paris Stock Exchange, Euronext Access, the Free Aftermarket, without raising money. What is the business of the company?**

Bd W.: Bonyf's mission is to improve the lives and comfort of people suffering from oral diseases through innovative oral products. The long phase of R&D has resulted in the establishment of a wide range of patented products. Their marketing has started, but it's still largely below what we can claim.

### **Boursier.com: What chemical active ingredients are these products based on?**

Bd W.: Bonyf's NitrAdine technology is a clinically proven disinfectant formulation that allows you to set up products without resorting to petrochemicals. NitrAdine is highly effective against microorganisms, commonly known as "tooth plaque" and is responsible for many problems for people who, for example, wear a toothbrush, and whose effects on serious diseases are also in doubt. certain as Alzheimer's. You should know that the mouth and especially the gums are a huge gateway into the body for bacteria.

### **Boursier.com: What are your main products?**

Bd W.: OlivaFix Gold is the world's first adhesive cream for dental prostheses. Its petrochemical and zinc free formulation is based on a sustainable, organic olive oil resource. This major innovation is patented, clinically proven and recognized by optimal consumers in a market dominated by competitive petrochemical and zinc based products. Second flagship product: PerioTabs is a revolutionary sweeping solution that reduces gingivitis, periodontitis, perimucositis and peri-implantitis, without the use of chlorhexidine. This product includes a bonyf core technology, NitrAdine. Products are manufactured at a bonyf production site in Switzerland according to strict international regulations to ensure consistent product quality.

### **Boursier.com: Why not decide on listing on a regulated fundraising-related marketplace?**

Bd W.: Here's the next step. And, hopefully, to follow the fundraising move to Euronext Growth, to essentially fund our commercial development. The first step on Euronext Access should enable us to strengthen our reputation by informing ourselves and our products, already on the market ... We were thinking about the IPO a few years ago, but we chose to take the time to do some good. clinical studies that validate the effects of our products.

### **Boursier.com: What are your key strategic priorities for the coming months?**

Bd W.: We aim for an ambitious marketing plan for commercial deployment in Europe for OlivaFix Gold and PerioTabs and, for each product, the first target country to be reached in 2022. We want the commercial dynamics for both countries increase this. This coincides with a policy of strategic partnerships with major players in the pharmaceutical industry to distribute innovative bonyf products. In our strategy, we do not exclude licensing agreements or patent assignments for many countries. Finally, we plan to keep our R&D effort with new products being developed.

Start investing your money in cryptocurrencies and get Free Bitcoin when you buy or sell 100\$ or more if you register in [Coinbase](#)